Spruce Biosciences Stock (NASDAQ:SPRB)

Revenue Ownership Financials Chart

Previous Close

$0.46

52W Range

$0.41 - $5.95

50D Avg

$0.49

200D Avg

$1.59

Market Cap

$18.65M

Avg Vol (3M)

$426.69K

Beta

2.41

Div Yield

SPRB Company Profile

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Oct 09, 2020

Website

SPRB Performance

SPRB Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$10.09M	-	-
Operating Income	$-51.99M	$-47.28M	$-42.07M
Net Income	$-47.92M	$-45.08M	$-42.69M
EBITDA	$-51.99M	$-45.76M	$-41.95M
Basic EPS	$-1.24	$-1.92	$-1.83
Diluted EPS	$-1.24	$-1.92	$-1.83

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

Ticker	Company
XFOR	X4 Pharmaceuticals, Inc.
VECT	VectivBio Holding AG
DAWN	Day One Biopharmaceuticals, Inc.
HOOK	HOOKIPA Pharma Inc.
TERN	Terns Pharmaceuticals, Inc.
INZY	Inozyme Pharma, Inc.
ELDN	Eledon Pharmaceuticals, Inc.
ABOS	Acumen Pharmaceuticals, Inc.